Eisai R&d Management Co., Ltd.

Yuki Karoji

Keigo Tanaka

Toshimi Okada

Satoshi Nagao

Setsuo Funasaka

Isao Ohashi

Yoshinobu Yamane

Yusuke Nakatani

The present invention provides a novel compound having FGFR inhibitory activity or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the same. Specifically, the present invention provides a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof: wherein n represents 0 to 2; A represents an arylene group or a heteroarylene group; G represents a single bond, an oxygen atom or &#x2014;CH&#x2014;; E represents a nitrogen-containing non-aromatic heterocycle; Rrepresents an alkoxy group or the like; Rrepresents a hydrogen atom or the like; and Rrepresents a hydrogen atom, an alkyl group, an alkoxy group or the like, with the proviso that when E represents an azetidine ring and Ror Ris present on a nitrogen atom on the azetidine ring, the Ror Rdoes not represent a hydrogen atom.

Monocyclic pyridine derivative

Growing community of inventors

Tsukuba, Japan

Yuki Karoji